18:56 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Abingworth's BioVentures VII fund closes at $315M, exceeding target

Abingworth Management Ltd. closed its BioVentures VII fund at $315 million, exceeding the fund's $300 million target. Funds will be invested in the U.S. and Europe. Abingworth's therapeutic interests for BioVentures VII include next-generation cell...
18:49 , Jul 13, 2018 |  BioCentury  |  Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
23:35 , Jul 9, 2018 |  BC Extra  |  Financial News

Abingworth closes BioVentures VII fund at $315M

Abingworth Management Ltd. closed its BioVentures VII fund at $315 million, exceeding the fund's $300 million target. Funds will be invested in the U.S. and Europe. Abingworth's therapeutic interests for BioVentures VII include next-generation cell...
19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
07:00 , Jul 25, 2005 |  BC Week In Review  |  Company News

Whatman management update

Whatman plc (LSE:WHM), Kent, U.K.   Business: Supply/Service   Departed: Timothy Haines, who was to join the company as CEO in September; he instead will become a partner at Abingworth Management Ltd.  ...
08:00 , Nov 20, 2000 |  BC Week In Review  |  Company News

Epigenomics GmbH board of directors update

(Scientific Advisory Board, B9; Financing, B18) Epigenomics GmbH, Berlin, Germany   Business: Enabling technology   Appointed: Jorg Neermann, partner at Deutsche Venture Capital Gessellschaft; Michael Steinmetz; partner at MPM Asset Management; and John Berriman, consultant...
07:00 , Apr 3, 2000 |  BioCentury  |  Finance

Dainty eaters

OXFORD - European biotech companies have had their best quarter since 1996, with an 83 increase in the market capitalization of the publicly quoted sector from $20 billion to $37 billion. However, while the stock...
07:00 , Oct 13, 1997 |  BioCentury  |  Finance

Burgeoning Euro venture funds

Europe's public markets for bioscience companies may be in the doldrums at the moment, but the European appetite for private investments probably has never been higher. In the past year, there has been an unprecedented...
08:00 , Mar 24, 1997 |  BioCentury  |  Finance

Those sizeable U.K. offerings

In an IPO market where many U.S. biotech companies are taking haircuts on their road shows, U.K.-based Cambridge Antibody Technology managed to raise £41.3 million (US$66 million). To provide a parallel, on Friday Cell Therapeutics...
08:00 , Feb 10, 1997 |  BioCentury  |  Finance

Blech resurfaces

Following more than two years of relative invisibility, investor David Blech has resurfaced, making $5.8 million in open market purchases in GeneMedicine (GMED) over the last two months. The 30 transactions, totaling 907,000 shares, could...